NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain

September 23, 2014

Media Advisory



The National Institutes of Health is convening a Pathways to Prevention workshop to assess the available scientific evidence on the long-term effectiveness and potential risks of opioids for treating chronic pain. Participants will be among the nation's top experts in the field of pain control and management from around the country, as well as key NIH scientists who focus on pain related research. An impartial, independent panel will identify research gaps and future research priorities. The workshop will seek to clarify:

-- Long-term effectiveness of opioids for treating chronic pain

-- Potential risks of opioid treatment in various patient populations

-- Effects of different opioid management strategies on outcomes related to addiction, abuse, misuse, pain, and quality of life

-- Effectiveness of risk mitigation strategies for opioid treatment

-- Future research needs and priorities to improve the treatment of pain with opioids.

The workshop is co-sponsored by the NIH Office of Disease Prevention (ODP), the NIH Pain Consortium, the National Institute on Drug Abuse, and the National Institute of Neurological Disorders and Stroke.

This workshop is free and open to the public. Registration> and additional information are available on the ODP website:


Monday, Sept. 29 from 8:30 a.m. to 5 p.m., and on Tuesday, Sept. 30 from 8:30 a.m. to 1:40 p.m.


Natcher Auditorium (Building 45) on the NIH campus, Bethesda, Maryland.


Chronic pain is a major public health problem, which is estimated to affect more than 100 million people in the United States and about 20-30 percent of the population worldwide. Opioids are powerful analgesics which are commonly used and found to be effective for many types of pain. However, opioids can produce significant side effects and long-term opioid use can result in physical dependence. This workshop will identify methodological and scientific weaknesses in the study of opioid treatment for chronic pain, suggest research needs, and move the field forward through an unbiased, evidence-based assessment. Visit the workshop website for more background information on this topic.


Please contact Deborah Langer in the NIH Office of Disease Prevention at 301-443-4569 or

The Office of the Director, the central office at NIH, is responsible for setting policy for NIH, which includes 27 Institutes and Centers. This involves planning, managing, and coordinating the programs and activities of all NIH components. The Office of the Director also includes program offices that are responsible for stimulating specific areas of research throughout NIH. Additional information is available at

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIH/Office of Disease Prevention

Related Chronic Pain Articles from Brightsurf:

Researchers are developing potential treatment for chronic pain
Researchers from the University of Copenhagen have developed a new way to treat chronic pain which has been tested in mice.

Molecular link between chronic pain and depression revealed
Researchers at Hokkaido University have identified the brain mechanism linking chronic pain and depression in rats.

How chikungunya virus may cause chronic joint pain
A new method for permanently marking cells infected with chikungunya virus could reveal how the virus continues to cause joint pain for months to years after the initial infection, according to a study published Aug.

Gastroesophageal reflux associated with chronic pain in temporomandibular joint
Gastroesophageal reflux (GERD) is associated with chronic, painful temporomandibular disorder -- pain in the temporomandibular joint -- and anxiety and poor sleep contribute to this association, according to a study in CMAJ.

One step closer to chronic pain relief
While effective drugs against chronic pain are not just around the corner, researchers from Aarhus University, Denmark, have succeeded in identifying a protein as a future potential target for medicinal drugs.

Gut bacteria associated with chronic pain for first time
In a paper published today in the journal Pain, a Montreal-based research team has shown, for the first time, that there are alterations in the bacteria in the gastrointestinal tracts of people with fibromyalgia.

Nearly 5.4 million cancer survivors suffer chronic pain
A new report finds about one in three cancer survivors (34.6%) reported having chronic pain, representing nearly 5.4 million cancer survivors in the United States.

New opioid speeds up recovery without increasing pain sensitivity or risk of chronic pain
A new type of non-addictive opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System accelerates recovery time from pain compared to morphine without increasing pain sensitivity, according to a new study published in the Journal of Neuroinflammation.

New target for chronic pain relief confirmed by scientists
A research group at Hiroshima University observed a potential new target for chronic pain treatment.

Menopause symptoms nearly double the risk of chronic pain
In addition to the other health conditions affected by estrogen, it has also been shown to affect pain sensitivity.

Read More: Chronic Pain News and Chronic Pain Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to